Beatrice Chemla (IMMA Health)
Overview
Beatrice Chemla is a co-founder and the Chief Executive Officer (CEO) of IMMA Health, a pioneering company in the field of women's health technology. IMMA Health is notable for developing an innovative at-home transvaginal ultrasound system aimed at transforming the fertility experience. Chemla, originally trained as a pharmacist, has over two decades of experience in the healthcare industry, including roles in market research and business development. Recognized for her leadership in femtech, she's been instrumental in advancing accessible healthcare solutions that empower women to manage their reproductive health autonomously.
Recent Developments
In recent years, Beatrice Chemla and IMMA Health have made significant strides in the femtech field:
-
2025: Secured a $1.6 million grant from the Israel Innovation Authority and received the Seal of Excellence from the European Innovation Council for their AI-powered transvaginal ultrasound technology. This dual recognition reflects the company's potential to impact reproductive healthcare significantly (source).
-
2025: Participated in the European Society of Human Reproduction and Embryology (ESHRE) conference, showcasing innovations in digital IVF and the integration of AI in reproductive health (source).
-
2024: Won recognition at the FemTech summit as a leading groundbreaking startup, highlighting the gender gap in technology and addressing women's healthcare needs (source).
-
2023: Continued development on their ultrasound system aimed at democratizing access to reproductive healthcare, indicating potential applications beyond fertility, such as endometriosis and PCOS management (source).
-
Chemla has been actively advocating for more women’s leadership in the tech industry, emphasizing the unique approaches and solutions driven by female leaders (source).
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Beatrice Chemla |
| Born | Not publicly available |
| Nationality | Franco-Israeli |
| Occupation | CEO and Co-founder of IMMA Health |
| Known For | Developing at-home transvaginal ultrasound systems |
| Net Worth | Not publicly available |
| Education | MBA in Healthcare Innovation from Reichman University, Israel |
Early Life and Education
Beatrice Chemla immigrated to Israel where she further pivoted her career towards healthcare technology and innovation. Prior to her entrepreneurial venture with IMMA Health, Chemla's professional journey was shaped by her extensive experience within the pharmaceutical industry, and healthcare strategy roles in major corporations. She pursued an executive Healthcare MBA at Reichman University in Israel, where she met Dr. Nadia Prisant, her future co-founder. Chemla’s educational background equipped her with the skills necessary to navigate the complexities of healthcare business development, laying a solid foundation for her eventual leap into entrepreneurship.
Career and Notable Achievements
Beatrice Chemla’s career is marked by her pivotal role in healthcare innovation:
-
2021: Founded IMMA Health, alongside Dr. Nadia Prisant and an engineer with a vision to transform women's reproductive health care.
-
Developed the first robotic, self-operated ultrasound system, designed for women to use at home, aimed at revolutionizing the IVF process (source).
-
The system incorporates AI-powered image analysis and a dedicated app, providing autonomy and privacy in fertility management.
-
Participated in and won the MassChallenge Israel competition, underlining her leadership in introducing groundbreaking femtech solutions (source).
-
Under Chemla's leadership, IMMA Health garnered significant attention, cementing its place within the health tech sector, and earning awards and recognitions at international health tech events.
Current Work and Impact
Beatrice Chemla continues to lead IMMA Health as it completes its seed funding round with plans to accelerate its technology's development. Her role involves overseeing strategic partnerships, technological innovations, and clinical trial preparations needed to push their product through regulatory approvals in the US and European markets. IMMA’s ultrasound platform is set to transform women's health by providing broader access to essential reproductive healthcare services and potentially addressing conditions like endometriosis and PCOS.
Conclusion
Beatrice Chemla stands at the forefront of the femtech revolution, driving significant change in how women's reproductive healthcare is accessed and delivered. Through her leadership, IMMA Health not only promises to improve fertility treatments but also to expand its technology platform's application to other aspects of women's health, reflecting its potential long-lasting impact on global health care. As Chemla continues her work, she symbolizes the growing recognition and importance of having more women leaders in the tech and healthcare industries, bringing unique perspectives and innovative solutions to longstanding healthcare challenges.